Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality
暂无分享,去创建一个
M. Hudson | M. Baron | Mianbo Wang | C. Thorne | P. Fortin | R. Laurent | S. Proudman | N. Ferdowsi | M. Nikpour | J. Walker | M. Rischmueller | J. Sahhar | J. Roddy | A. Sturgess | W. Stevens | N. Khalidi | K. Morrisroe | J. Zochling | J. Pope | G. Major | T. Rodríguez-Reyna | M. Larché | L. Schrieber | L. Croyle | K. Tymms | S. Lester | D. Robinson | A. Masetto | E. Sutton | G. Gyger | V. Thakkar | M. Fritzler | J. de Jager | G. Strickland | C. Hill | G. Ngian | N. Richard | D. Smith | P. Nash | Geneviève Gyger | G Gyger | P. Youseff
[1] M. Gosho,et al. Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation , 2018, Statistical methods in medical research.
[2] D. Mar,et al. Gastrointestinal and Hepatic Disease in Systemic Sclerosis. , 2018, Rheumatic diseases clinics of North America.
[3] Per B. Brockhoff,et al. lmerTest Package: Tests in Linear Mixed Effects Models , 2017 .
[4] H. Uchi,et al. Pathogenesis of systemic sclerosis—current concept and emerging treatments , 2017, Immunologic research.
[5] M. Hudson,et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort , 2017, Arthritis & rheumatology.
[6] S. Jimenez,et al. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis , 2017, Alimentary pharmacology & therapeutics.
[7] J. Varga,et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. , 2016, Seminars in arthritis and rheumatism.
[8] F. Mendoza,et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. , 2016, American journal of physiology. Gastrointestinal and liver physiology.
[9] G. Riemekasten,et al. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course , 2016, Expert review of clinical immunology.
[10] Y. Allanore,et al. Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease , 2015, Arthritis care & research.
[11] M. Hudson,et al. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. , 2015, Seminars in arthritis and rheumatism.
[12] M. Hsieh,et al. Reduced incidence of Crohn’s disease in systemic sclerosis: a nationwide population study , 2015, BMC Musculoskeletal Disorders.
[13] M. Hudson,et al. 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group , 2015, Arthritis care & research.
[14] M. Hudson,et al. Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects , 2014, The Journal of Rheumatology.
[15] X. Corbella,et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.
[16] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[17] C. Bascoul-Mollevi,et al. Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study , 2014, Health and Quality of Life Outcomes.
[18] M. Mayes,et al. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .
[19] M. Baron,et al. The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review , 2013, The Journal of Rheumatology.
[20] Bodo Winter,et al. Linear models and linear mixed effects models in R with linguistic applications , 2013, ArXiv.
[21] J. Gordon,et al. Low prevalence of coeliac disease in patients with systemic sclerosis: a cross-sectional study of a registry cohort. , 2013, Rheumatology.
[22] N. McHugh,et al. Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools , 2012, Clinical Rheumatology.
[23] M. Omair,et al. Effect of Gastrointestinal Manifestations on Quality of Life in 87 Consecutive Patients with Systemic Sclerosis , 2012, The Journal of Rheumatology.
[24] R. Steele,et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis , 2012, Arthritis care & research.
[25] M. Baron,et al. Gastrointestinal Manifestations of Scleroderma: Recent Progress in Evaluation, Pathogenesis, and Management , 2012, Current Rheumatology Reports.
[26] S. Laurberg,et al. Faecal incontinence in patients with systemic sclerosis: is an impaired internal anal sphincter the only cause? , 2011, Scandinavian journal of rheumatology.
[27] T. Skare,et al. Celiac disease screening in patients with scleroderma. , 2011, Arquivos de gastroenterologia.
[28] E. Feierl,et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.
[29] R. Adams,et al. New Australian population scoring coefficients for the old version of the SF-36 and SF-12 health status questionnaires , 2010, Quality of Life Research.
[30] M. Majdan,et al. Gastrointestinal involvement in patients with systemic sclerosis. , 2010, Polskie Archiwum Medycyny Wewnetrznej.
[31] Ami A. Shah,et al. Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension , 2010, The Journal of Rheumatology.
[32] A. Forbes,et al. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. , 2009, Rheumatology.
[33] R. Domsic,et al. Gastrointestinal Manifestations of Systemic Sclerosis , 2008, Digestive Diseases and Sciences.
[34] Alan C. Wilson,et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. , 2008, The Journal of rheumatology.
[35] N. Kamatani,et al. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. , 2007, The Journal of rheumatology.
[36] T. Krieg,et al. Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.
[37] C. Schentag,et al. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. , 2006, The Journal of rheumatology.
[38] R. Hays,et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. , 2005, The Journal of rheumatology.
[39] T. Medsger,et al. Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.
[40] M. Storr,et al. Autoantibody Profile in Progressive Systemic Sclerosis as Markers for Esophageal Involvement , 2001, Journal of clinical gastroenterology.
[41] T. Medsger,et al. Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.
[42] R. Sjogren. Gastrointestinal features of scleroderma. , 1996, Current opinion in rheumatology.
[43] R. Sjogren,et al. Gastrointestinal motility disorders in scleroderma. , 1994, Arthritis and rheumatism.
[44] A. Silman,et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.
[45] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[46] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[47] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[48] S. Guiducci,et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. , 2015, Annals of the rheumatic diseases.
[49] D. Farge,et al. Évaluation de la qualité de vie par le MOS-SF36 dans la sclérodermie systémique , 2004 .
[50] P. Lachenbruch,et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. , 1998, The Journal of rheumatology.
[51] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .
[52] M. Camilleri,et al. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. , 1989, Gastroenterology.